Metabolic subtyping reveals PDIK1L as a dual-functional regulator of progression and PARP inhibitor sensitivity in prostate cancer
Metabolic stratification reveals the C2 subtype as a high-risk prostate cancer group with unique therapeutic vulnerabilities. PDIK1L emerges as a dual-functional biomarker driving tumor progression and modulating treatment efficacy, offering a novel target for precision therapeutic strategies.
Authors
- Yonghao Chen (ORCID: https://orcid.org/0000-0003-0205-1816)
- Anwaier Aihetaimujiang
- Qintao Ge (ORCID: https://orcid.org/0000-0001-5040-6699)
- Bin Qin (ORCID: https://orcid.org/0000-0001-8244-127X)
- Jiahe Lu (ORCID: https://orcid.org/0000-0002-3555-1991)
- Hailiang Zhang (ORCID: https://orcid.org/0000-0002-8050-2494)
- Ji Zhang (ORCID: https://orcid.org/0000-0001-7005-6980)
- Wenhao Xu (ORCID: https://orcid.org/0000-0001-6878-4663)
- Jianfeng Yang
- Dingwei Ye (ORCID: https://orcid.org/0000-0003-4974-3780)
- Zhongyuan Wang (ORCID: https://orcid.org/0000-0002-5530-0380)
Institutions
- Shanghai Medical College of Fudan University (CN)
- Fudan University (CN)
- West China Medical Center of Sichuan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Longhua Hospital Shanghai University of Traditional Chinese Medicine (CN)
- Shanghai Traditional Chinese Medicine Hospital (CN)
- Wuxi Taihu Hospital (CN)
Publication Details
- Journal
- Frontiers in Cell and Developmental Biology
- Published
- 2025-11-04
- DOI
- https://doi.org/10.3389/fcell.2025.1674844
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shanghai Anti-Cancer Association
- Beijing Xisike Clinical Oncology Research Foundation
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- National Science and Technology Major Project